Back to Search
Start Over
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2relapsed/refractory AML: a randomized phase 3 trial
- Source :
- Blood; January 2023, Vol. 141 Issue: 2 p156-167, 12p
- Publication Year :
- 2023
-
Abstract
- •EFS was meaningfully improved with enasidenib vs CCR; OS was confounded by early dropout and use of subsequent AML therapies.•Enasidenib provided meaningful morphologic and hematologic responses vs CCR in this heavily pretreated older R/R mutant-IDH2AML population.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 141
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs60225874
- Full Text :
- https://doi.org/10.1182/blood.2021014901